miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways
Lung adenocarcinoma (LUAD) is one of the most common malignancies worldwide. Combination chemotherapy with cisplatin (CDDP) plus pemetrexed (PEM) remains the predominant therapeutic regimen; however, chemoresistance greatly limits its curative potential. Here, through CRISPR-Cas9 screening, we ident...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , , , |
---|---|
Format: | Buch |
Veröffentlicht: |
Elsevier,
2022-06-01T00:00:00Z.
|
Schlagworte: | |
Online-Zugang: | Connect to this object online. |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Online
Connect to this object online.3rd Floor Main Library
Signatur: |
A1234.567 |
---|---|
Exemplar 1 | Verfügbar |